These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A sensitive, accurate assay for extrinsic pathway inhibitor (EPI) activity in rabbit plasma: paradoxical effect of excess exogenous factor X. Warr TA; Rao LV; Rapaport SI Thromb Res; 1990 Aug; 59(4):773-82. PubMed ID: 2080494 [TBL] [Abstract][Full Text] [Related]
45. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Lindahl AK; Abildgaard U; Stokke G Thromb Res; 1990 Aug; 59(3):651-6. PubMed ID: 2237832 [No Abstract] [Full Text] [Related]
46. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Abildgaard U; Lindahl AK; Sandset PM Haemostasis; 1991; 21(4):254-7. PubMed ID: 1794751 [TBL] [Abstract][Full Text] [Related]
47. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Bajaj MS; Kuppuswamy MN; Saito H; Spitzer SG; Bajaj SP Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8869-73. PubMed ID: 2247459 [TBL] [Abstract][Full Text] [Related]
48. Identification of an endothelial cell product as an inhibitor of tissue factor activity. Colburn P; Buonassisi V In Vitro Cell Dev Biol; 1988 Nov; 24(11):1133-6. PubMed ID: 3192507 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal IgM antibody expressing lupus anticoagulant activity. Skjønsberg OH; Wisløff F; Godal HC Thromb Res; 1990 May; 58(3):349-52. PubMed ID: 2112789 [No Abstract] [Full Text] [Related]
51. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Novotny WF; Brown SG; Miletich JP; Rader DJ; Broze GJ Blood; 1991 Jul; 78(2):387-93. PubMed ID: 2070076 [TBL] [Abstract][Full Text] [Related]
52. The current status of coagulation. Luchtman-Jones L; Broze GJ Ann Med; 1995 Feb; 27(1):47-52. PubMed ID: 7741998 [TBL] [Abstract][Full Text] [Related]
53. [Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome]. Małyszko JS; Małyszko J; Myśliwiec M Pol Arch Med Wewn; 1999 Apr; 101(4):301-5. PubMed ID: 10740407 [TBL] [Abstract][Full Text] [Related]
54. [Vascular function tests for diagnosis of blood coagulation disorders]. Maruyama I Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):839-43. PubMed ID: 1919197 [No Abstract] [Full Text] [Related]
55. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Warr TA; Warn-Cramer BJ; Rao LV; Rapaport SI Blood; 1989 Jul; 74(1):201-6. PubMed ID: 2473796 [TBL] [Abstract][Full Text] [Related]
56. [Serum thermostable and thermolabile inhibitors of tissue thromboplastin]. Byshevskiĭ ASh; Rudzevich EL Vopr Med Khim; 1977; 23(4):519-25. PubMed ID: 919377 [TBL] [Abstract][Full Text] [Related]
57. No effect of factor Xa or tissue thromboplastin and factor VII on the activation of plasminogen. Wiman B; Holm T; Prydz H Thromb Res; 1976 Nov; 9(5):523-5. PubMed ID: 136768 [No Abstract] [Full Text] [Related]
58. An inhibitor of factor VII from human placenta. Uszynski M; Godal HC Scand J Haematol; 1971; 8(5):392-5. PubMed ID: 5134836 [No Abstract] [Full Text] [Related]
59. Altered shear stress on endothelial cells leads to remodeling of extracellular matrix and induction of angiogenesis. Russo TA; Banuth AMM; Nader HB; Dreyfuss JL PLoS One; 2020; 15(11):e0241040. PubMed ID: 33211705 [TBL] [Abstract][Full Text] [Related]
60. Enhanced inhibition of tissue factor by the extended form of an endothelial cell glycoprotein (an extrinsic pathway inhibitor). Colburn P; Crabb JW; Buonassisi V J Cell Physiol; 1991 Aug; 148(2):320-6. PubMed ID: 1880157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]